A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis

NCT01395004 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Langerhans Cell Histiocytosis

Interventions

DRUG: GSK2110183

Sponsor

GlaxoSmithKline